Sugi Predict

Sugi Predict / Compounds / SCHEMBL693172

SCHEMBL693172

SCHEMBL693172

CC(C)(C)OC(=O)N1CCN(C(=O)C(F)(F)F)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ HPGD P15428 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ NR1H2 P55055 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27005874 0.95 MAPT (0.52) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL12321494 0.89 USP2 (0.55) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL698803 0.85 USP2 (0.69) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL18294 0.85 USP2 (0.69) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL26537610 0.85 USP2 (0.51) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL10200814 0.84 USP2 (0.58) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL484976 0.83 CYP11B2 (0.49) USP2SMN1; SMN2EPHX2
SCHEMBL16383805 0.81 HRH3 (0.38) USP2SMN1; SMN2HPGDMAPTEPHX2
SCHEMBL31042678 0.81 USP2 (0.47) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL28034443 0.81 USP2 (0.55) USP2SMN1; SMN2HPGDMAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 — — US disclosed
US-20230072397-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-03-09 — — US disclosed
CN-110088098-B Quinazolinone PARP-1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2022-04-15 — — CN disclosed
CN-113924292-A Antimicrobial compounds and methods 库扎环球有限责任公司 2022-01-11 — — CN disclosed
CN-113825748-A Antimicrobial compounds and methods 库扎环球有限责任公司 2021-12-21 — — CN disclosed
EP-3911644-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2021-11-24 — — EP disclosed
EP-3911643-A1 ANTIMICROBIAL COMPOUNDS AND METHODS Curza Global LLC (US) 2021-11-24 — — EP disclosed
WO-2020150372-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 — — WO disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 — — WO disclosed
US-20050238614-A1 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids ELAN PHARMACUTICALS, INC. 2005-10-27 — — US disclosed
WO-2005097162-A2 STEROID SPARING AGENTS AND THEIR USE ELAN PHARMACEUTICALS, INC. (US) 2005-10-20 — — WO disclosed
WO-2005070921-A1 POLYETHYLENE GLYCOL CONJUGATES OF HETEROCYCLOALKYL CARBOXAMIDO PROPANOIC ACIDS ELAN PHARMACEUTICALS, INC. (US) 2005-08-04 — — WO disclosed
US-20050074451-A1 Methods and compositions for treating rheumatoid arthritis ELAN PHARMACEUTICALS, INC. (US) 2005-04-07 — — US disclosed
US-20050065192-A1 Methods and compositions for treating rheumatoid arthritis ELAN PHARMACEUTICALS, INC. (US) 2005-03-24 — — US disclosed
WO-2005000244-A2 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS ELAN PHARMACEUTICALS, INC. (US) 2005-01-06 — — WO disclosed
WO-2005000246-A2 METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS ELAN PHARMACEUTICALS, INC. (US) 2005-01-06 — — WO disclosed
EP-0921800-B1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL MYERS SQUIBB CO (US) 2004-04-14 — — EP disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 — — US disclosed
US-4247549-A Piperazine-1-carboxylic acid esters possessing antidepressant or analgesic activity ICI AMERICAS INC. (US) 1981-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 USP2 2798/4885SMN1; SMN2 4817/4885HPGD 1474/4885
US-20050238614-A1 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids VCAM1, ICAM1, EPCAM USP2 2936/4885SMN1; SMN2 2357/4885HPGD 1740/4885
US-20050065192-A1 Methods and compositions for treating rheumatoid arthritis VCAM1, ICAM1, ITGA4 USP2 4200/4885SMN1; SMN2 4636/4885HPGD 3029/4885
US-20230072397-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 USP2 2798/4885SMN1; SMN2 4817/4885HPGD 1474/4885
US-20050074451-A1 Methods and compositions for treating rheumatoid arthritis VCAM1, ICAM1, ITGA4 USP2 4200/4885SMN1; SMN2 4636/4885HPGD 3029/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 USP2 2798/4885SMN1; SMN2 4817/4885HPGD 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.